Arcus Biosciences stock jumps on Goldman upgrade as traders eye JPM Healthcare stage
New York, Jan 13, 2026, 13:22 (EST) — Regular session Arcus Biosciences shares rose nearly 5% on Tuesday after Goldman Sachs upgraded the biotech to “Buy” and lifted its price target. The stock was up 4.8% at $22.32 in early afternoon trading. (TipRanks) The call hit in the middle of the J.P. Morgan Healthcare Conference week, when investors often press…